aspirin + clopidogrel + ticagrelor

This is a triple antiplatelet therapy regimen consisting of aspirin, clopidogrel, and ticagrelor. Each component works through different mechanisms to prevent platelet aggregation and blood clot formation. Aspirin inhibits cyclooxygenase, preventing thromboxane A2 production. Clopidogrel and ticagrelor are both P2Y12 receptor antagonists, with ticagrelor being more potent and having a more consistent antiplatelet effect. This triple combination is not a standard formulated product but represents an intensified antiplatelet approach that would carry significantly increased bleeding risks compared to dual antiplatelet therapy.

Other names

RAPID EXTEND regimen